Ascendis Pharma A (ASND) Asset Writedowns and Impairment (2022 - 2025)

Ascendis Pharma A (ASND) has 4 years of Asset Writedowns and Impairment data on file, last reported at -$2.6 million in Q4 2025.

• For the quarter ending Q4 2025, Asset Writedowns and Impairment fell 2563.45% year-over-year to -$2.6 million; the trailing twelve-month figure through Mar 2026 stood at -$2.6 million (down 133.2% YoY), and the FY2025 full-year result was $6.1 million, up 6343.75% from the prior year.
• Asset Writedowns and Impairment retreated to -$2.6 million in Q4 2025, from $7.9 million in the prior quarter.
• In the past five years, Asset Writedowns and Impairment ranged from a high of $8.4 million in Q4 2023 to a low of -$2.6 million in Q4 2025.
• A 4-year average of $1.5 million and a median of $8066.2 in 2022 frame the typical range for Asset Writedowns and Impairment.
• Across the five-year window, Asset Writedowns and Impairment jumped 37652.89% in 2023 and sank 2563.45% in 2025, its largest moves.
• Tracing ASND's Asset Writedowns and Impairment over 4 years: stood at -$22445.4 in 2022, then jumped by 37652.89% to $8.4 million in 2023, then plunged by 101.15% to -$97242.2 in 2024, then slumped by 2563.45% to -$2.6 million in 2025.
• Business Quant data shows ASND's Asset Writedowns and Impairment at -$2.6 million in Q4 2025, $7.9 million in Q1 2025, and -$97242.2 in Q4 2024.